A study to evaluate the feasibility of performing genomic testing of rare cancers to match the cancer to treatment. GeNOmic MatchINg treATment fOr Rare cancers (NOMINATOR).
- Conditions
- Rare cancer.Cancer - Any cancer
- Registration Number
- ACTRN12616001000493
- Lead Sponsor
- Melbourne Health
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 100
* Patients aged over 18 years, with signed informed consent and ability to comply with protocol requirements
* Patients with Eastern Cooperative Oncology Group (ECOG) performance status 0-1
* Patients with a life expectance of >12 weeks
* Access to tumour tissue is available from core biopsy or surgical resection from a disease site
* Histologically confirmed rare histopathology diagnosis according to the RARECARE group definition
* Malignancy where little evidence-based care or standard of care therapies exist
* Tumour type associated with a poor outcome
* Patients who are unable, or unwilling to consent to the study.
* Patients who have a concurrent active malignancy other than adequately treated non-melanomatous skin cancer, early prostatic adenocarcinoma treated with curative intent or non-invasive carcinoma / in-situ neoplasm of the cervix or breast. Patients with a previous history of malignancy will be eligible provided they have been disease-free for >5 years.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method